Cannabis + Tobacco Co-Use Triples Psychosis Risk in High-Risk Adults

A new multisite study published in Nature Mental Health on May 12, 2026 has produced one of the cleanest signals to date about a long-suspected interaction in cannabis research: when cannabis and tobacco are used together, they appear to raise the risk of developing psychotic disorders far more than either substance does on its own — and the effect is particularly pronounced in people already at clinical high risk for psychosis.

The Vanderbilt-led analysis found that cannabis-and-tobacco co-use was associated with a nearly threefold increase in the chance of transitioning to a full psychotic disorder over a two-year follow-up. For a research field that has historically struggled to disentangle the two substances — they are so often used together that isolating cannabis's independent effects is notoriously difficult — this study is a notable methodological step forward.

What the Study Measured

The research was led by Heather Ward, MD, assistant professor of Psychiatry and Behavioral Sciences and director of Neuromodulation Research at Vanderbilt Health, working with collaborators across the North American Prodrome Longitudinal Study (NAPLS) consortium. NAPLS is one of the largest ongoing efforts to track people at "clinical high risk" for psychosis — individuals who have warning signs such as attenuated psychotic symptoms but who have not yet developed schizophrenia or another full psychotic disorder.

For this paper, the team analyzed substance use patterns over a two-year period in 734 individuals at clinical high risk for psychosis, plus 278 healthy controls. Participants reported their cannabis and tobacco use, and researchers measured how many in each group went on to develop a psychotic disorder during follow-up.

Crucially, the team defined "co-use" carefully: using the two substances at the same time, on the same occasion, or within a defined time frame where their effects might overlap pharmacologically. That definition is tighter than older studies, which often grouped anyone who used both substances in the same month into a single "co-use" bucket regardless of timing.

The Headline Finding

The headline number — a nearly threefold increased risk of psychosis transition in co-users at clinical high risk — is striking even by the standards of psychiatric epidemiology. Cannabis use alone has been associated with elevated psychosis risk in dozens of prior studies, with most meta-analyses showing roughly a two-fold relative risk for heavy or high-potency use in vulnerable populations. Tobacco use independently shows a smaller but real association with psychotic disorders.

What this paper adds is the synergy. Co-use's risk was substantially greater than either substance alone, suggesting that the two products are not simply additive — they appear to interact pharmacologically in a way that amplifies harm in already vulnerable brains.

The researchers proposed a mechanism: smoking tobacco and cannabis together increases pulmonary absorption of THC, the main psychoactive compound in cannabis. Higher THC exposure is itself a known risk factor for transient psychotic symptoms. Add nicotine — which alters dopamine signaling in the same brain regions implicated in psychosis — and the combination may be doing more than each substance does alone.

What It Doesn't Say

This is the part where careful interpretation matters. The study does not say cannabis causes psychosis in the general population. It does not say casual adult cannabis users are at elevated risk of schizophrenia. And it does not say tobacco is safe — separate evidence already places tobacco among the most harmful legal substances.

The study population was specifically people at clinical high risk for psychosis. That means they had warning signs — attenuated symptoms, family history, or other markers — placing them in a higher-baseline-risk group than the general population. The findings should be read as a signal for that vulnerable subpopulation, not a universal claim about cannabis safety.

It is also an observational study. Researchers measured what participants did and what happened, but they did not randomly assign anyone to cannabis or tobacco. That means confounders — early trauma, family history, polysubstance use, baseline mental health — are controlled statistically but cannot be ruled out entirely.

Even so, the signal in this population is strong, replicated in multiple sites, and consistent with prior basic-science work on THC-nicotine interactions in animal models.

Clinical Implications

For clinicians working with adolescents and young adults — the demographic most at risk for first-episode psychosis — the practical implication is direct. Screening for cannabis use in patients already showing prodromal symptoms is standard. Screening specifically for cannabis-tobacco co-use, and counseling patients who report it about the elevated risk, may now become a more pointed conversation.

The researchers also note that stopping cannabis and tobacco co-use may improve mental health symptoms, and that it is possible that stopping co-use could reduce the risk of developing psychosis in the first place. That is a hypothesis the study can support but cannot prove — a randomized trial of cessation in high-risk adults would be needed for that.

For cannabis users without any psychosis risk factors, the takeaway is more about practice than alarm. Mixing tobacco into joints — a common practice in Europe and increasingly in the U.S. — is biologically distinct from smoking cannabis alone. The pharmacology genuinely is different, and consumers who prefer to keep cannabis and tobacco separate appear to have evidence on their side.

How the Cannabis Industry Will Respond

Expect the legal cannabis industry to read this study carefully. Industry research arms have spent years building the case that regulated cannabis use, particularly in adult consumers without psychosis risk factors, is comparable in harm profile to moderate alcohol use. Findings that strengthen the case against high-potency or co-use exposure in vulnerable subpopulations are not contradictions of that broader argument; they are reasons to differentiate practice within it.

Practical industry responses could include clearer co-use warnings on dispensary educational materials, point-of-sale screening prompts in adult-use markets that allow tobacco sales, and continued push for limits on the highest-THC concentrates that account for most acute psychiatric ER presentations. New consumers can also lean on guides like the first-time buyer guide to make safer choices about format and dose before they ever step into a shop.

What to Watch Next

NAPLS continues, and follow-up papers from the consortium are likely to drill deeper into dose-response relationships — how much cannabis-and-tobacco co-use is associated with what level of risk — and into whether the synergistic effect holds in lower-risk populations. The Vanderbilt team has also signaled interest in imaging studies that would look at structural and functional brain changes in co-users versus single-substance users, which could clarify whether the mechanism is primarily about THC exposure, nicotine effects, or genuine interaction at the receptor level.

For now, the May 2026 paper joins a growing body of evidence that the way cannabis is consumed — alone, with other substances, at what potency, and at what age — matters as much as whether it is consumed at all.

Key Takeaways

• A new study in Nature Mental Health found cannabis-and-tobacco co-use was associated with a nearly threefold increased risk of developing psychosis in adults already at clinical high risk.
• The research, led by Vanderbilt's Dr. Heather Ward, analyzed 734 high-risk individuals and 278 controls in the NAPLS consortium over two years.
• The proposed mechanism involves enhanced THC absorption from co-smoking and synergistic effects of nicotine and THC on dopamine signaling.
• The findings apply specifically to a clinical high-risk population, not to all cannabis users.
• Practical takeaway: co-using cannabis and tobacco — including in mixed joints — appears pharmacologically distinct from using either substance alone, and is a worthwhile target for clinical screening and consumer awareness.

Choosing where to shop matters as much as what you choose. Budpedia's directory of verified cannabis dispensaries lists only operators that pass state-license checks and publish lab results — a baseline that makes harm-reduction conversations easier to start.